FXN and Friedreich ataxia: The downregulation of Suv4-20h expression by siRNA or the pharmacological inhibition of its catalytic activity was shown to restore FXN expression in primary FRDA patient-derived cells, identifying Suv4-20h1 as a potential therapeutic target for the disease.